Form 8-K - Current report:
SEC Accession No. 0001193125-24-284167
Filing Date
2024-12-23
Accepted
2024-12-23 16:00:28
Documents
14
Period of Report
2024-12-20
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d480921d8k.htm   iXBRL 8-K 27734
2 EX-3.1 d480921dex31.htm EX-3.1 192532
  Complete submission text file 0001193125-24-284167.txt   391277

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA atra-20241220.xsd EX-101.SCH 2855
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE atra-20241220_lab.xml EX-101.LAB 18741
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atra-20241220_pre.xml EX-101.PRE 11711
16 EXTRACTED XBRL INSTANCE DOCUMENT d480921d8k_htm.xml XML 3863
Mailing Address 2380 CONEJO SPECTRUM ST SUITE 200 THOUSAND OAKS CA 91320
Business Address 2380 CONEJO SPECTRUM ST SUITE 200 THOUSAND OAKS CA 91320 805-623-4244
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

EIN.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36548 | Film No.: 241573502
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)